Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression
This ML-NMR suggests that zanubrutinib offers improved PFS compared to ibrutinib and acalabrutinib in both general and high-risk R/R CLL populations. OS results were uncertain due to limited follow-up.
Authors
- Walter Bouwmeester (ORCID: https://orcid.org/0000-0001-9592-5548)
- Leyla Mohseninejad
- Keri Yang
- Milica Jevdjevic (ORCID: https://orcid.org/0000-0002-2443-401X)
- Jeroen P Jansen
- Mazyar Shadman
- Rhys Williams
- Sheng Xu
Institutions
- National University of Misiones (AR)
- Fred Hutch Cancer Center (US)
- Precision Research (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1080/13696998.2025.2609514
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00